Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PILOT ANTI-CMV CLINICAL TRIAL
2024-520020-28-00Phase 2Authorised
- Sponsor
- IDIVAL
- Start
- Jan 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic cytomegalovirus-specific memory T cells in cytomegalovirus disease (CMV), sponsored by IDIVAL. Primary endpoint: Incidence of CMV infection at day 100 post-transplant. Planned start Jan 2025; status: authorised.
02
Drugs
allogeneic cytomegalovirus-specific memory T cells
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2024-520020-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520020-28-00.